{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Efficacy and Safety of PCSK9 Inhibitors Now Measured In Years with No Change in Scale of Clinical Benefit - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"1KeVXscahZ\"><a href=\"https:\/\/themedicalxchange.com\/en\/2016\/06\/07\/national-lipid-association-nla-2016-scientific-ses\/\">Efficacy and Safety of PCSK9 Inhibitors Now Measured In Years with No Change in Scale of Clinical Benefit<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2016\/06\/07\/national-lipid-association-nla-2016-scientific-ses\/embed\/#?secret=1KeVXscahZ\" width=\"600\" height=\"338\" title=\"&#8220;Efficacy and Safety of PCSK9 Inhibitors Now Measured In Years with No Change in Scale of Clinical Benefit&#8221; &#8212; The Medical Xchange\" data-secret=\"1KeVXscahZ\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2016\/06\/2361_NLA_2016_EN_Fig1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"New Orleans \u2013 New evidence presented at the NLA 2016 Scientific Sessions demonstrated that PCSK9 inhibitors provide unprecedented control of low-density lipoprotein cholesterol (LDL-C) for as long as patients remain on therapy. After 2 years of follow-up in a phase 3 trial, the reduction in LDL-C with a PCSK9 inhibitor was comparable to those first reported after 24 weeks. In this large multicenter, randomized study, which enrolled patients at high risk of cardiovascular (CV) events, the type and rate of adverse events at 2 years remained low and comparable to rates reported at any earlier time point."}